

**WP9 meeting at EHA 2009, Berlin**

**June 4, 2009**

**Internationales Congress Centrum (ICC) Berlin  
Neue Kantstraße 1, 14057 Berlin  
Salon Koch, 10:45 – 12:45**

**AGENDA**

**Introduction** (T. Barbui)

**Consensus definition of response in PV and ET** (G. Barosi)

**Key issues of bone marrow pathology in MPN** (A.Schmitt-Graff)

**Clinical trials in MPD:**

- Update of the CYTO-PV trial (G. Finazzi)
- HDACs and JAK2 inhibitors in Europe (A. Rambaldi )
- Randomized trial hydroxyurea vs peg-IFN-alfa 2a in PV and ET (J.J. Kiladjian)

**EXELS – an observational study of anagrelide in high-risk ET** (G. Birgegard)

**Registry of pregnancies** (M. Griesshammer)

**Acute leukemia secondary to MPD** (C. Rinaldi)

**Harmonization of JAK2V617F assays** (A. Vannucchi, D. Grimwade)

**Proposals for the next period**

**Discussion**

**Closing remarks** (J.J. Kiladjian)